Halozyme Therapeutics Inc. (HALO)

14.46
0.54 3.60
NASDAQ : Health Technology
Prev Close 15.00
Open 15.19
Day Low/High 14.29 / 15.31
52 Wk Low/High 14.29 / 21.48
Volume 1.10M
Avg Volume 848.50K
Exchange NASDAQ
Shares Outstanding 144.56M
Market Cap 2.17B
EPS 0.50
P/E Ratio 41.67
Div & Yield N.A. (N.A)

Latest News

Halozyme Reports Third Quarter 2018 Financial Results

Halozyme Reports Third Quarter 2018 Financial Results

- ENHANZE® Licensed to Roche for up to Three Additional Targets, Includes $25 Million Upfront Payment, Plus the Potential for Future Milestone and Royalty Payments -

Halozyme Names Albert Kildani As Vice President Investor Relations And Corporate Communications

Halozyme Names Albert Kildani As Vice President Investor Relations And Corporate Communications

SAN DIEGO, Nov. 6, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc.

Halozyme Licenses New ENHANZE® Targets For $25 Million Upfront Payment, Future Milestones And Royalties

Halozyme Licenses New ENHANZE® Targets For $25 Million Upfront Payment, Future Milestones And Royalties

SAN DIEGO, Oct. 30, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc.

Halozyme Announces First Clinical Dosing In Bristol-Myers Squibb's Phase 1 Trial Of BMS-986179 With Enhanze® Technology

Halozyme Announces First Clinical Dosing In Bristol-Myers Squibb's Phase 1 Trial Of BMS-986179 With Enhanze® Technology

SAN DIEGO, Oct. 25, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc.

Halozyme Provides Summary Results Of Data For PEGPH20 Combination Treatments Presented At ESMO 2018 Congress

Halozyme Provides Summary Results Of Data For PEGPH20 Combination Treatments Presented At ESMO 2018 Congress

SAN DIEGO, Oct. 22, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc.

Halozyme To Host Third Quarter 2018 Financial Results Conference Call

Halozyme To Host Third Quarter 2018 Financial Results Conference Call

SAN DIEGO, Oct. 10, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc.

Halozyme Publication In The Journal Clinical Cancer Research Highlights New Nonclinical Data Supporting Multiple Effects Of PEGPH20 On The Tumor Microenvironment

Halozyme Publication In The Journal Clinical Cancer Research Highlights New Nonclinical Data Supporting Multiple Effects Of PEGPH20 On The Tumor Microenvironment

- In animal models PEGPH20 increased vascular volume and perfusion, decreased hypoxia and depleted an important proangiogenic growth factor VEGF-A165 through hyaluronan degradation -

Halozyme Therapeutics To Participate In Upcoming Investor Conference

Halozyme Therapeutics To Participate In Upcoming Investor Conference

SAN DIEGO, Sept. 20, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc.

Halozyme Announces Approval Of Subcutaneous Formulation Of Trastuzumab (Herceptin®) In Canada

Halozyme Announces Approval Of Subcutaneous Formulation Of Trastuzumab (Herceptin®) In Canada

SAN DIEGO, Sept. 17, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc.

Halozyme Appoints Bernadette Connaughton To Board Of Directors

Halozyme Appoints Bernadette Connaughton To Board Of Directors

SAN DIEGO, Sept. 10, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc.

Halozyme Names Benjamin Hickey As Chief Commercial Officer

Halozyme Names Benjamin Hickey As Chief Commercial Officer

SAN DIEGO, Sept. 5, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc.

Halozyme Therapeutics To Participate In Upcoming Investor Conferences

Halozyme Therapeutics To Participate In Upcoming Investor Conferences

SAN DIEGO, Aug. 22, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc.

Halozyme Reports Second Quarter 2018 Results

Halozyme Reports Second Quarter 2018 Results

-- Revenue of $35.2 Million Includes a 36 Percent Increase in Royalty Revenue on a Reported Basis --

Halozyme Therapeutics To Participate In Upcoming Healthcare Conference

Halozyme Therapeutics To Participate In Upcoming Healthcare Conference

SAN DIEGO, July 26, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will be presenting at the Canaccord Genuity 38 th Annual Growth Conference in Boston on...

Phase 3 Study Of Subcutaneous Pertuzumab And Trastuzumab Initiated Using Halozyme's ENHANZE® Technology

Phase 3 Study Of Subcutaneous Pertuzumab And Trastuzumab Initiated Using Halozyme's ENHANZE® Technology

SAN DIEGO, July 26, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that Genentech, a member of the Roche Group, has dosed the first patient in...

First Week Of March 2019 Options Trading For Halozyme Therapeutics (HALO)

First Week Of March 2019 Options Trading For Halozyme Therapeutics (HALO)

Investors in Halozyme Therapeutics Inc saw new options begin trading this week, for the March 2019 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 233 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

FDA Accepts Biologics License Application For Subcutaneous Formulation Of Herceptin

FDA Accepts Biologics License Application For Subcutaneous Formulation Of Herceptin

SAN DIEGO, July 11, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.

Halozyme To Host Second Quarter 2018 Financial Results Conference Call

Halozyme To Host Second Quarter 2018 Financial Results Conference Call

SAN DIEGO, July 6, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will webcast its Quarterly Update Conference Call for the second quarter 2018 on Tues.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ATAX, COR, GPRK, KWR, NYLD Downgrades: CKH, CUTR, CYD, DRQ, EDAP, FLXS, GOLD, HALO, HDB, IRDM, KND, MSCC, XRX Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ACSF, ATRC, BKE, CRSP, HALO Downgrades: GIFI, GTE, MGI, NNI, RBBN, SHAK, SPPI Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Halozyme Therapeutics Stock Sees Short Interest Decrease By 12%

Halozyme Therapeutics Stock Sees Short Interest Decrease By 12%

The most recent short interest data has been released for the 01/31/2018 settlement date, which shows a 1,401,809 share decrease in total short interest for Halozyme Therapeutics Inc , to 10,232,867, a decrease of 12.05% since 01/12/2018. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

It's Bad, but It's Not a Crash: Cramer's 'Mad Money' Recap (Friday 2/2/18)

It's Bad, but It's Not a Crash: Cramer's 'Mad Money' Recap (Friday 2/2/18)

In a special edition of Mad money, Jim Cramer examines this brutal decline and lays out the game plan for next week -- live from Minneapolis ahead of the Super Bowl.

Shopify, Kinder Morgan, Pfizer: 'Mad Money' Lightning Round

Shopify, Kinder Morgan, Pfizer: 'Mad Money' Lightning Round

Jim Cramer highlights Shopify, Kinder Morgan, Thermo Fisher Scientific, Radius Health, Merck, Pfizer and more.

Halozyme Therapeutics Reaches Analyst Target Price

Halozyme Therapeutics Reaches Analyst Target Price

In recent trading, shares of Halozyme Therapeutics Inc have crossed above the average analyst 12-month target price of $20.11, changing hands for $20.36/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Roku, Sierra Wireless, Visa, Cimarex Energy: 'Mad Money' Lightning Round

Roku, Sierra Wireless, Visa, Cimarex Energy: 'Mad Money' Lightning Round

Jim Cramer focuses on Roku, Sierra Wireless, Visa, Cimarex Energy, First Solar, Halozyme Therapeutics.

Good Things Come to Those Who Buy: Cramer's 'Mad Money' Recap (Monday 12/18/17)

Good Things Come to Those Who Buy: Cramer's 'Mad Money' Recap (Monday 12/18/17)

Don't buy big here and don't buy all at once, but it's not too late to ride this bull to profits, says Jim Cramer.

Sage Therapeutics Skyrockets on Data for Depression Drug -- Biotech Movers

Sage Therapeutics Skyrockets on Data for Depression Drug -- Biotech Movers

The Cambridge, Mass.-based firm unveiled positive top-line results from its Phase 2 study of SAGE-217 in patients with moderate to severe major depressive disorder.

TheStreet Quant Rating: C (Hold)